Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea. Its lead product is obeticholic acid, OCA, also known as 6-ethyl-chenodeoxycholic acid or INT-747, marketed as Ocaliva. OCA is a potent first-in-class farnesoid X receptor (FXR) agonist. Ocaliva is approved in the US and the EU for use in primary biliary cholangitis.


Company Growth (employees)
Type
Public
HQ
New York, US
Founded
2002
Size (employees)
456 (est)+13%
Intercept Pharmaceuticals was founded in 2002 and is headquartered in New York, US

Key People at Intercept Pharmaceuticals

Mark Pruzanski

Mark Pruzanski

Chief Executive Officer & President
Luciano Adorini

Luciano Adorini

Chief Scientific Officer

Intercept Pharmaceuticals Office Locations

Intercept Pharmaceuticals has offices in New York, Wien, Gouda, Mississauga and in 8 other locations
New York, US (HQ)
10 Hudson Yards
Zürich, CH
1 Kalanderpl.
Madrid, ES
135 Paseo De La Castellana
Lisboa, PT
Centro Empresarial Torres De Lisboa Rua Tomás Da Fonseca, Torre G, 1º Piso
Milano, IT
6 Largo Francesco Richini
London, GB
2 Pancras Rd

Intercept Pharmaceuticals Data and Metrics

Intercept Pharmaceuticals Financial Metrics

Intercept Pharmaceuticals's revenue was reported to be $21 m in Q1, 2017
USD

Revenue (Q1, 2017)

21 m

Gross profit (Q1, 2017)

21 m

Gross profit margin (Q1, 2017), %

100%

Net income (Q1, 2017)

(89.9 m)

EBIT (Q1, 2017)

(84 m)

Market capitalization (21-Jul-2017)

3.2 b

Cash (31-Mar-2017)

67 m
Intercept Pharmaceuticals's current market capitalization is $3.2 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

25 m

R&D expense

153.9 m

General and administrative expense

273.6 m

Operating expense total

427.5 m

EBIT

(235.7 m)(453.3 m)(223.7 m)(402.5 m)

EBIT margin, %

(1613%)

Interest expense

14.2 m

Net Income

(186 m)(283.2 m)(226.4 m)(412.8 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

5.5 m5.2 m21 m

Cost of goods sold

97 k

Gross profit

21 m

Gross profit Margin, %

100%

R&D expense

14.9 m27.4 m28 m28.3 m27.5 m37.4 m41.3 m43.8 m43.8 m

General and administrative expense

8 m9.1 m13.1 m21 m24.7 m90.4 m42.3 m44.4 m61.1 m

Operating expense total

22.9 m36.5 m41.1 m49.3 m52.2 m127.8 m83.6 m88.2 m104.9 m

EBIT

(83 m)(84 m)

EBIT margin, %

(1604%)(399%)

Interest expense

(7.1 m)(7.2 m)

Net Income

33.5 m(35.8 m)(39.4 m)(47.9 m)(50.9 m)(126.7 m)(77.3 m)(88.8 m)(89.9 m)
USDY, 2009Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016

Cash

4.4 m15.4 m17.7 m45.5 m13.4 m20 m32.7 m43.7 m

Accounts Receivable

9.1 m

Inventories

2.7 m6.1 m13.6 m2.3 m

Current Assets

147.6 m245.8 m641.7 m707.9 m

Total Assets

150.3 m254.1 m655.8 m739.3 m

Accounts Payable

17.6 m

Total Debt

341.4 m

Current Liabilities

8.9 m15.2 m47.4 m78.5 m

Total Liabilities

424.3 m

Additional Paid-in Capital

268.3 m700.4 m1.3 b1.4 b

Retained Earnings

(469.2 m)(695.6 m)(1.1 b)

Total Equity

82.4 m314.9 m

Debt to Equity Ratio

1.1 x

Debt to Assets Ratio

0.5 x

Financial Leverage

1.8 x2.3 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

45 m18.1 m104.4 m88.3 m72.4 m49.2 m51.7 m105.2 m67 m

Accounts Receivable

10.6 m

Inventories

2.1 m

Current Assets

306.6 m279.1 m410.4 m741 m702.5 m574.9 m505.3 m794.6 m635 m

Total Assets

310.8 m286 m421.6 m753.9 m716.7 m593.4 m524.2 m812.3 m668 m

Current Liabilities

11.9 m16.5 m18.2 m23.8 m32.2 m99.3 m102.2 m54.5 m72.7 m

Additional Paid-in Capital

688.5 m695.6 m904.7 m1.3 b1.3 b1.3 b1.3 b1.4 b1.4 b

Retained Earnings

(398.5 m)(434.4 m)(508.6 m)(556.5 m)(607.4 m)(822.3 m)(899.6 m)(988.4 m)(1.2 b)

Total Equity

289.9 m261.1 m395.9 m722.9 m677.9 m488.3 m416.7 m414.9 m240.2 m

Financial Leverage

1.1 x1.1 x1.1 x1 x1.1 x1.2 x1.3 x2 x2.8 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(67.8 m)(283.2 m)(226.4 m)(412.8 m)

Depreciation and Amortization

105.7 k442.8 k1.7 m3.8 m

Accounts Receivable

(9.1 m)

Inventories

(1.7 m)(2.3 m)

Accounts Payable

7.3 m

Cash From Operating Activities

(28 m)(87.7 m)(162.9 m)(342.4 m)

Cash From Investing Activities

(70.2 m)(96.6 m)(389.5 m)(60.1 m)

Cash From Financing Activities

66.1 m191 m565.5 m414.4 m

Interest Paid

4.2 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

33.5 m(35.8 m)(39.4 m)(47.9 m)(50.9 m)(126.7 m)(77.3 m)(88.8 m)(89.9 m)

Accounts Receivable

10.6 m

Inventories

2.1 m
USDY, 2017

Revenue/Employee

46.2 k

Financial Leverage

2.8 x

Intercept Pharmaceuticals Market Value History

Intercept Pharmaceuticals Online and Social Media Presence

Intercept Pharmaceuticals News and Updates

Intercept Pharmaceuticals Company Life and Culture

You may also be interested in